Functionally, isocitrate dehydrogenase 2 (IDH2) regulates mRNA m6A modification by activating FTO; on the other hand, it can down-regulate the m6A level of WNT7B mRNA and increase the expression of WNT7B, thus activating the Wnt signaling pathway, which ultimately facilitates the growth of tumor cells in MM in vitro and shortens the overall survival of patients. This evidence concerns the gene FTO and Miyoshi myopathy.